Clinical trial inclusion in patients with relapsed/refractory neuroblastoma following the European Precision Cancer Medicine trial MAPPYACTS

耐火材料(行星科学) 医学 神经母细胞瘤 临床试验 癌症 肿瘤科 人口 内科学 生物 环境卫生 物理 天体生物学 遗传学 细胞培养
作者
Jordane Chaix,Gudrun Schleiermacher,Nadège Corradini,Nicolás André,Estelle Thébaud,Marion Gambart,Anne Sophie Defachelles,Natacha Entz‐Werlé,Pascal Chastagner,Émilie De Carli,Stéphane Ducassou,Judith Landman‐Parker,Tiphaine Adam de Beaumais,Alicia Larive,Stefan Michiels,Gilles Vassal,Dominique Valteau‐Couanet,Birgit Geoerger,Pablo Berlanga
出处
期刊:European Journal of Cancer [Elsevier BV]
卷期号:201: 113923-113923 被引量:1
标识
DOI:10.1016/j.ejca.2024.113923
摘要

Abstract

Introduction

Despite poor survival for patients with relapsed or refractory neuroblastoma, only 10–16% of patients are reported to be included in early phase trials. This study aimed to explore the impact of molecular profiling within the prospective precision cancer medicine trial MAPPYACTS (NCT02613962) on subsequent early phase trial recruitment and treatment by matched targeted therapies in this population.

Methods and materials

Clinical data from all French patients with relapsed/refractory neuroblastoma enrolled in MAPPYACTS were analyzed for subsequent matched/non-matched targeted treatment based on clinical tumor board (CMTB) recommendations.

Results

From 93 patients with neuroblastoma included in French centers, 78 (84%) underwent whole exome and RNA sequencing and were discussed in the CMTB. Higher rate of successful sequencing analysis was observed in patients with relapsed disease compared to those with refractory disease (p = 0.0002). Among the 50 patients that presented with a new disease relapse/progression after the CMTB recommendations, 35 patients (70%) had at least one actionable alteration identified on the tumor at the time of relapse. Eighteen patients (36%) were included in an early phase clinical trial, 11 of these with a matched agent, 7 with a non-matched treatment; 13 patients were included in the AcSé ESMART trial. Five patients (10%) received a matched targeted therapy outside a clinical trial.

Conclusion

Patients with neuroblastoma in the European MAPPYACTS trial were more likely to be included in early phase trials compared to previous reports. Early deep sequencing at first treatment failure, comprehensive therapeutic discussions in molecular tumor boards and innovative trials like AcSé -ESMART improve access to innovative therapies for patients with relapsed/refractory neuroblastoma. Clinical trial registration: NCT02613962
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
FLZLC发布了新的文献求助10
2秒前
研友_84mlkL完成签到,获得积分10
4秒前
4秒前
退而求其次完成签到,获得积分10
5秒前
阿胡发布了新的文献求助30
5秒前
6秒前
害羞书易完成签到,获得积分20
6秒前
思源应助牧觅云采纳,获得10
6秒前
烟花应助qq采纳,获得10
9秒前
monoklatt发布了新的文献求助10
9秒前
10秒前
10秒前
研友_84mlkL发布了新的文献求助10
10秒前
12秒前
文献达人发布了新的文献求助10
13秒前
小蘑菇应助吃吃采纳,获得10
14秒前
14秒前
彭于晏应助zs采纳,获得10
15秒前
桥豆麻袋发布了新的文献求助10
15秒前
16秒前
17秒前
赵嘉钰完成签到,获得积分10
19秒前
SYLH应助研友_LNVX1L采纳,获得10
20秒前
复杂的兔子完成签到,获得积分10
20秒前
论文顺利完成签到,获得积分10
20秒前
lii应助上官靖采纳,获得10
21秒前
qq发布了新的文献求助10
22秒前
还好还好发布了新的文献求助10
22秒前
22秒前
23秒前
改论文不看剧完成签到,获得积分10
23秒前
搜集达人应助1234采纳,获得10
23秒前
zs完成签到,获得积分10
25秒前
都好都好好的完成签到,获得积分10
26秒前
27秒前
处处铃铛响完成签到,获得积分10
27秒前
量子星尘发布了新的文献求助10
27秒前
俗丨发布了新的文献求助10
27秒前
论文顺利发布了新的文献求助10
28秒前
zs发布了新的文献求助10
28秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
Toward a Combinatorial Approach for the Prediction of IgG Half-Life and Clearance 500
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Picture Books with Same-sex Parented Families: Unintentional Censorship 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3969940
求助须知:如何正确求助?哪些是违规求助? 3514642
关于积分的说明 11175298
捐赠科研通 3249947
什么是DOI,文献DOI怎么找? 1795178
邀请新用户注册赠送积分活动 875617
科研通“疑难数据库(出版商)”最低求助积分说明 804891